自体血循管预防血透病人首次使用综合征的疗效分析

Efficacy analysis on autologous blood circulation pipe in preventing first use syndrome of hemodialysis patients

目的 研究使用自体血循管预防血透病人首次使用综合征的可行性,提高透析质量、减轻患者痛苦及医疗费用.方法 将维持性血液透析的患者156人共1158例次,按照透析时间分为对照组和实验组.对照组按常规血透流程操作,实验组在对新的透析器和管路进行常规预冲后使用患者自体血密闭式循管10 ～ 15 min,对两组患者血透过程中首次使用综合征（First-useSyndrome,FUS）发生率及体外凝血发生率进行对比.结果 对照组在560例次透析治疗的病人中,共发生FUS 23例次（4.11％）,而实验组在598例次透析治疗的病人中,共发生FUS 5例次（0.84％）.FUS发生率实验组明显低于对照组,两组比较差异有统计学意义（P＜0.01）,而体外凝血发生率则两组无明显改变,差异无统计学意义（P＞0.05）.结论 使用患者自体血循管能有效预防血透病人血透过程中首次使用综合征的发生,且不增加出血及体外凝血现象风险.

Objective To study the feasibility of using autologous blood circulation pipe syndrome in preventing the first use syndrome （FUS） of hemodialysis patients,improve the quality of dialysis,reduce patients＇ sufering and medical expenses.Methods The sample pool of 156 maintenance hemodialysis patients with 1158 times of hemodialysis,were divided into control and experimental groups.Normal hemodialysis practices were applied to control group,while 10-15 min of autologous blood circulation pipe after the preshoot of dialyser and pipes practices were applied to experimental group.A comparison of possibility of FUS and in vitro coagulation was conducted between the two groups.Results In the control group with patients given dialysis treatment in 560 cases,there were 23 cases of FUS,the rate was 4.11％,while the experimental group treated dialysis patients in 598 cases,there were 5 cases of FUS,the rate was 0.84％.FUS incidence in the experimental group was significantly lower than that of the control group,the difference was statistically significant （P ＜ 0.01）,whereas the incidence of the in vitro coagulation showed no significant change,the difference was not statistically significant （P ＞ 0.05）.Conclusion The application of autologous blood circulation pipe is effective in preventing FUS during hemodialysis treatment,meanwhile no bleeding or in vitro coagulation risk increases.